English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 18 January 2019, 14:33 JST
Share:
    

Source: Eisai
Eisai's Notification Regarding Results of Voluntary Retirement Program

TOKYO, Jan 18, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that the application period for the first round of the voluntary retirement program it announced on October 25, 2018, has ended and hereby discloses the results as follows:

1. Outline of Voluntary Retirement Program
a) Eligibility Criteria:
Employees 45 or older who have worked at Eisai for five consecutive years or more as of April 1, 2018
b) Effective Date of Retirement:
First round: March 31, 2019; Second round: March 31, 2020;
Third round: March 31, 2021
c) Number of Applicants Sought:
First round: Approximately 100*
d) Application Period:
First round: From December 11, 2018 to December 21, 2018 (may be subject to change based on the application situation). The application periods for the second and third rounds will cover a similar period of time each fiscal year.
e) Preferential Conditions:
A premium will be added to the normal retirement allowance. In addition, applicants will also have the option to receive job-placement assistance.

*The number of applicants sought for the second and third round will be determined in consideration of the outcome of the application situation.

2. Number of Confirmed Applicants / Total Amount of Premium Retirement Payments (First Round)
a) Number of Confirmed Applicants:
300 applicants
b) Total Amount of Premium Retirement Payments:
Approx. 6.6 billion yen

*Judging from the application situation, the application deadline was shortened from December 21, 2018 to December 19, 2018.

3. Impact on Financial Performance
The sum total of premium retirement payments associated with the implementation of the first round of this program will be recorded as expenses in the settlement of accounts for the third quarter of the fiscal year ending March 31, 2019. The full-year consolidated financial results forecasts for the fiscal year ending March 31, 2019 previously announced on November 1, 2018 includes a certain level for these expenses, and based on recent trends in business performance and other factors, there is no change to the full-year consolidated financial results forecasts.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
Monday, 26 January 2026, 11:37 JST
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
2026年1月26日 8時40分 JST
エーザイとバイオジェン、抗 Aβ抗体レカネマブの皮下注射製剤「LEQEMBI(R) IQLIK(TM)」について、早期アルツハイマー病に対する初期療法からの投与を可能とする生物製剤承認一部変更申請が米国 FDA に受理され、優先審査に指定
Wednesday, 21 January 2026, 16:44 JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
Tuesday, 13 January 2026, 9:50 JST
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
Tuesday, 6 January 2026, 10:43 JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
More news >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575